Clinical efficacy and therapy response prediction of neoadjuvant dalpiciclib plus letrozole in postmenopausal patients with HR+/HER2- stage II-III breast cancer (DARLING 01): a single-arm, open-label, exploratory study
Dalpiciclib combined with letrozole demonstrated promising antitumor activity and an acceptable safety profile in postmenopausal patients with HR+/HER2- breast cancer. The identification of TFRC, SCUBE2, and MMP11A as predictive biomarkers provides insights into the potential for personalized neoadjuvant treatment strategies.
Authors
- Chao Yang (ORCID: https://orcid.org/0000-0002-7023-3577)
- Ruizhen Luo
- Xinping Zhou (ORCID: https://orcid.org/0000-0002-7920-1395)
- Xiaochun Wang (ORCID: https://orcid.org/0000-0002-3216-5710)
- Zunyi Wang (ORCID: https://orcid.org/0000-0002-6560-250X)
- Yueping Liu (ORCID: https://orcid.org/0000-0002-4582-114X)
- Li Ma (ORCID: https://orcid.org/0000-0002-9090-1667)
- Haifeng Cai
- Xiangshun Kong
- Lina Zhang (ORCID: https://orcid.org/0000-0002-4308-6698)
- Cuizhi Geng (ORCID: https://orcid.org/0000-0001-5541-5412)
- Yuntao Li (ORCID: https://orcid.org/0000-0001-8788-7537)
- Zhisheng Zhang (ORCID: https://orcid.org/0000-0002-0481-2589)
- Jiaxing Wang (ORCID: https://orcid.org/0000-0002-6674-4948)
- Meiqi Wang (ORCID: https://orcid.org/0000-0003-2417-1480)
- Jie Ma (ORCID: https://orcid.org/0000-0002-5729-1297)
- Jianjun Han (ORCID: https://orcid.org/0000-0003-2885-3470)
- Jiajie Shi (ORCID: https://orcid.org/0000-0002-6118-4742)
- Yanshou Zhang
Institutions
- Hebei University of Engineering (CN)
- Hebei Medical University (CN)
- Handan College (CN)
- Hebei North University (CN)
- Tangshan People's Hospital (CN)
- Cangzhou Central Hospital (CN)
- Fourth Hospital of Hebei Medical University (CN)
- Xingtai People's Hospital (CN)
- Affiliated Hospital of Hebei University (CN)
Publication Details
- Journal
- Breast Cancer Research
- Published
- 2025-02-13
- DOI
- https://doi.org/10.1186/s13058-025-01976-0
- Citations
- 3
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 4.56
Funders
- Jiangsu Hengrui Medicine
- Beijing Xisike Clinical Oncology Research Foundation